Cupid promoter Halwasiya lifts personal stake to 33.45% as Q1 profit jumps 194%

Cupid chairman Aditya Kumar Halwasiya bought 803,000 shares, taking his personal holding to 33.45%. The consumer healthcare and FMCG company reported Q1 FY27 net profit of Rs 44.15 crore, up 194% year-on-year, on total income growth of 142%, and guided for FY27 revenue of Rs 725-750 crore.

— Source published Wed, 19 Aug, 2026, 10:22 IST · First seen Wed, 19 Aug, 2026, 10:40 IST · Source Business Today · Latest

What happened

Cupid Ltd · Cupid chairman Aditya Kumar Halwasiya increased his personal holding to 33.45% through open-market purchases. The consumer healthcare and FMCG

Key facts

  • Aditya Kumar Halwasiya acquired 803,000 shares (0.06% equity)
  • Halwasiya's personal stake rose to 33.45%
  • Promoter and promoter-group stake: 46.40%
  • Two disclosed purchases totalled 2,198,538 shares
  • Q1 FY27 net profit: Rs 44.15 crore, up 194% YoY
  • Q1 FY27 total income: Rs 156.98 crore, up 142% YoY
  • Q1 FY27 EBITDA: Rs 60.06 crore, up 265% YoY
  • EBITDA margin: 39%, versus 28% in Q1 FY26
  • FY27 revenue guidance: Rs 725-750 crore
  • FY27 net-profit guidance: Rs 210-225 crore

Why this matters

Cupid’s accelerating scale, improving earnings profile and committed promoter ownership could make it a more credible partnership or acquisition candidate in consumer healthcare and FMCG.

What to watch

  • Q2 and Q3 revenue run rate relative to the Rs 725-750 crore FY27 target.
  • EBITDA, net-profit and gross-margin trends after expansion spending.
  • Operating cash flow, receivable days, inventory build and working-capital intensity.
  • Further promoter purchases, pledging activity or changes in promoter shareholding.
  • Volume growth and distribution expansion across core consumer-health products.
  • Management commentary on capacity, export/institutional orders, competitive pricing and demand conditions.
  • Increase investor outreach around revenue mix, margin drivers and the pathway to FY27 guidance.
  • Deploy promoter-buying signal to strengthen distributor, supplier and institutional stakeholder confidence.
  • Prioritize inventory, receivables and production-capacity discipline to convert rapid reported growth into cash flow.
  • Evaluate selective brand-building and distribution expansion in consumer healthcare and FMCG categories while protecting gross margins.
  • Prepare clearer disclosure separating recurring operating performance from one-off, base-effect or financial-income contributions.